Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity-Reference-Cited by-同舟云学术

Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity

Published:2020-12 Issue:5 Volume:40 Page:
ISSN:0261-4189
Container-title:The EMBO Journal
language:en
Short-container-title:The EMBO Journal

Author:

Caddy Sarah L¹²^ORCID,Vaysburd Marina¹,Papa Guido¹,Wing Mark¹,O’Connell Kevin¹,Stoycheva Diana³,Foss Stian⁴⁵,Terje Andersen Jan⁴⁵,Oxenius Annette³,James Leo C¹^ORCID

Affiliation:

1. MRC Laboratory of Molecular Biology Cambridge UK

2. CITIID Department of Medicine University of Cambridge Cambridge UK

3. Department of Biology Institute of Microbiology ETH Zurich Zurich Switzerland

4. Department of Immunology University of Oslo and Oslo University Hospital Rikshospitalet Oslo Norway

5. Institute of Clinical Medicine and Department of Pharmacology University of Oslo and Oslo University Hospital Oslo Norway

Funder

Medical Research Council

Publisher

EMBO

Subject

General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,Molecular Biology,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/embj.2020106228

Reference42 articles.

1. Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates

2. Impairment and delay of neutralizing antiviral antibody responses by virus‐specific cytotoxic T cells;Battegay M;J Immunol,1993

3. Correction: Impaired Antibody Response Causes Persistence of Prototypic T Cell–Contained Virus

4. Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus

5. TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the role of the nucleocapsid protein in SARS-CoV-2 pathogenesis: From viral life cycle to vaccine development;International Journal of Biological Macromolecules;2024-11

2. FAT10 inhibits TRIM21 to down-regulate antiviral type-I interferon secretion;Life Science Alliance;2024-07-08

3. Permanent lymphocyte subset elimination upon a single dose of AAV-delivered depletion antibody dissects immune control of chronic viral infection;2024-06-21

4. Beyond bNAbs: Uses, Risks, and Opportunities for Therapeutic Application of Non-Neutralising Antibodies in Viral Infection;Antibodies;2024-04-03

5. A programmable targeted protein-degradation platform for versatile applications in mammalian cells and mice;Molecular Cell;2024-04